Zymeworks Common Stock Stock Analysis

Zymeworks Stock Analysis Notes

About 99.0% of the company outstanding shares are owned by institutional investors. The company recorded a loss per share of 0.84. Zymeworks Common Stock had not issued any dividends in recent years. Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada. Zymeworks operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 284 people. For more information please call Kenneth Galbraith at 302 274 8744 or visit https://www.zymeworks.com.

Zymeworks Common Stock Investment Alerts

Zymeworks Largest EPS Surprises

View All Earnings Estimates

Zymeworks Common Environmental, Social, and Governance (ESG) Scores

Zymeworks Stock Institutional Investors

Note, although Zymeworks Common's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Zymeworks Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.76 B.

Zymeworks Profitablity

The company has Profit Margin (PM) of (0.47) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.8) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.8.

Management Efficiency

Zymeworks Common Stock has return on total asset (ROA) of (0.0998) % which means that it has lost $0.0998 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1846) %, meaning that it created substantial loss on money invested by shareholders. Zymeworks Common's management efficiency ratios could be used to measure how well Zymeworks Common manages its routine affairs as well as how well it operates its assets and liabilities. As of February 6, 2026, Return On Tangible Assets is expected to decline to -0.26. In addition to that, Return On Capital Employed is expected to decline to -0.35. At present, Zymeworks Common's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 5.02, whereas Non Currrent Assets Other are forecasted to decline to about 5.7 M.

Technical Drivers

As of the 6th of February, Zymeworks Common maintains the Mean Deviation of 2.88, market risk adjusted performance of (1.04), and Downside Deviation of 3.23. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Zymeworks Common Stock, as well as the relationship between them. Please check out Zymeworks Common Stock variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Zymeworks Common Stock is priced fairly, providing market reflects its latest price of 22.02 per share. Given that Zymeworks Common Stock has jensen alpha of 0.3228, we strongly advise you to confirm Zymeworks Common Stock's prevalent market performance to make sure the company can sustain itself at a future point.

Zymeworks Common Stock Price Movement Analysis

Zymeworks Common Stock Insider Trading Activities

Zymeworks Common Outstanding Bonds

Zymeworks Common Predictive Daily Indicators

Zymeworks Common Forecast Models

Zymeworks Common's time-series forecasting models are one of many Zymeworks Common's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Zymeworks Common's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Zymeworks Common Bond Ratings

Zymeworks Common Stock financial ratings play a critical role in determining how much Zymeworks Common have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Zymeworks Common's borrowing costs.

Zymeworks Common Stock Debt to Cash Allocation

Zymeworks Common Stock currently holds 18.51 M in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. Zymeworks Common Stock has a current ratio of 3.22, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Zymeworks Common's use of debt, we should always consider it together with its cash and equity.

Zymeworks Common Total Assets Over Time

Zymeworks Common Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Zymeworks Common uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Zymeworks Common Debt Ratio

2.36

It looks as if most of the Zymeworks Common's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Zymeworks Common's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Zymeworks Common, which in turn will lower the firm's financial flexibility.

Zymeworks Common Corporate Bonds Issued

Zymeworks Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Zymeworks Common prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Zymeworks shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Zymeworks Common. By using and applying Zymeworks Stock analysis, traders can create a robust methodology for identifying Zymeworks entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Zymeworks analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Zymeworks analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Zymeworks Common Stock stock analysis indicators help investors evaluate how Zymeworks Common stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Zymeworks Common shares will generate the highest return on investment. By understating and applying Zymeworks Common stock analysis, traders can identify Zymeworks Common position entry and exit signals to maximize returns.

When running Zymeworks Common's price analysis, check to measure Zymeworks Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zymeworks Common is operating at the current time. Most of Zymeworks Common's value examination focuses on studying past and present price action to predict the probability of Zymeworks Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zymeworks Common's price. Additionally, you may evaluate how the addition of Zymeworks Common to your portfolios can decrease your overall portfolio volatility.